Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
-
REGULATORY Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
-
COMMENTARY Delving into Potential Implications of Envisaged Price Revision Overhaul
September 12, 2022
-
ORGANIZATION FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
-
BUSINESS Lagevrio’s Normal Distribution to Start from Sept. 16: MSD
September 9, 2022
-
ACADEMIA University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
-
REGULATORY Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
-
ORGANIZATION Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
September 7, 2022
-
BUSINESS Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
-
REGULATORY MHLW Study Group to Ponder Support Measures for Stable Generic Supplies
September 6, 2022
-
ORGANIZATION Chuikyo Payer Rep Eyes 5%-Plus Discrepancy Threshold or Broader Coverage: 2023 Off-Year Re-Pricing
September 5, 2022
-
ACADEMIA Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
September 5, 2022
-
REGULATORY Japan to Give Omicron Boosters to Elderly from Mid-September
September 5, 2022
-
ORGANIZATION FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
September 2, 2022
-
REGULATORY Japan to Supply AstraZeneca’s Evusheld Only for COVID-19 Prevention
September 2, 2022
-
REGULATORY New Expert Panel on Drug Distribution and Pricing Boots Up; 2-Step Proposals Eyed for Off-Year Revision, 2024 Reform
September 1, 2022
-
ORGANIZATION JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
August 31, 2022
-
REGULATORY University of Tokyo Selected as Flagship R&D Site to Orchestrate Japan’s Vaccine Efforts: SCARDA Project
August 31, 2022
-
REGULATORY Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
August 30, 2022
-
REGULATORY AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…